2. Signalwege
  3. Neuronal Signaling
  4. Cholinesterase (ChE)
  5. BChE Isoform

BChE

Butyrylcholinesterase (BuChE; acylcholine acylhydrolase), also known as nonspecific cholinesterase or pseudocholinesterase, is a serine hydrolase present in almost all mammalian tissues with the highest levels detected in plasma and liver. BChE hydrolyzes acetylcholine and all chemicals containing ester bonds, including anesthetics such as succinylcholine and procaine and drugs such as cocaine and heroin. BChE is found in glia and white matter in the brain and is also associated with neurons, particularly in the hippocampus, amygdala, and thalamus. BChE was also found in amyloid plaques and neurofibrillary tangles (NFTs), which suggests that the protein may be involved in the pathogenesis of Alzheimer’s disease.

BChE Verwandte Produkte (202):

Art. -Nr. Produktname Wirkung Reinheit
  • HY-161512
    hAChE/hBACE-1-IN-4
    		Inhibitor
    hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against hAChE and hBACE-1 enzymes (hAChE, IC50=0.283 μM; hBACE-1, IC50=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research.
  • HY-180783
    AChE/BChE/MAO-A-IN-1
    		Inhibitor
    AChE/BChE/MAO-A-IN-1 (Compound 5c) is a multi-target inhibitor with IC₅₀ values for AChE, BChE, and MAO-A of 78.7, 22.63, and 0.84 μM respectively. AChE/BChE/MAO-A-IN-1 can be used for the research of Alzheimer's disease.
  • HY-180797
    S1R agonist/BChE-IN-1
    		Inhibitor
    S1R agonist/BChE-IN-1 (Compound 7c) is a S1R (IC50: 19 nM) agonist and selective BChE (IC50: 37 nM for hBChE) inhibitor. S1R agonist/BChE-IN-1 can be used in the research of Alzheimer's disease.
  • HY-118729
    Difeterol
    		Inhibitor
    Difeterol is an antihistamine agent and histamine-1 receptor antagonist. Difeterol inhibits BChE. Difeterol can be used in the research of Alzheimer's disease.
  • HY-172219
    CUR-IPA
    		Inhibitor
    CUR-IPA is a cholinesterase inhibitor, with IC50 of 5.99, 59.30, and 60.66 μM for eAChE (electric eel), hAChE (human), and hBChE (human), respectively. CUR-IPA can scavenge free radicals and has antioxidant activity. CUR-IPA can be used in the research of cognitive dysfunction.
  • HY-168731
    AChE/BChE-IN-25
    		Inhibitor
    AChE/BChE-IN-25 (Compound 6e) is the orally active inhibitor for hAChE and eqBChE with IC50 of 7.9 nM and 0.79 nM. AChE/BChE-IN-25 exhibits antioxidant activity, that scavenges free radical with IC50 of 22.91 μM. AChE/BChE-IN-25 exhibits neuroprotective effects by reducing mitochondrial and cellular oxidative stress in the Drosophila Alzheimer's disease model. AChE/BChE-IN-25 ameliorates Scopolamine (HY-N0296)-induced spatial and cognitive memory impairment in mouse model.
  • HY-174399
    AChE/BChE-IN-27
    		Inhibitor
    AChE/BChE-IN-27 is a blood-brain barrier-permeable mixed inhibitor (Pe = 4.12) of AChE and BChE, with IC50 values of 3.72 μM and 9.65 μM, respectively. AChE/BChE-IN-27 has potent antioxidant activity with an IC50 value of 6.32 μM in the DPPH (HY-112053) assay and also exhibits potent in vitro antioxidant activity. AChE/BChE-IN-27 exhibits metal chelating properties. AChE/BChE-IN-27 has neuroprotective potential against oxidative stress. AChE/BChE-IN-27 significantly reduces intracellular reactive oxygen species (ROS). In in vivo experiments, AChE/BChE-IN-27 effectively restored AChE and BChE levels, improved cognition, and can be used for Alzheimer's disease (AD).
  • HY-180819
    AChE/BChE-IN-33
    		Inhibitor
    AChE/BChE-IN-33 (Compound 3N) is a dual-target inhibitor of AChE and BChE, with IC50 values of 12.81 and 44.54 nM respectively. AChE/BChE-IN-33 exhibits selective cytotoxicity against SH-SY5Y cells. AChE/BChE-IN-33 can be used for the study of Alzheimer's disease and neuroblastoma.
  • HY-162671
    BuChE-IN-12
    		Inhibitor
    BuChE-IN-12 is a selective BuChE inhibitor (IC50=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease.
  • HY-185347
    AChE-IN-114
    		Inhibitor
    AChE-IN-114 is a selective AChE inhibitor and shows weak inhibitory activity for BChE. AChE-IN-114 can be used for the research of alzheimer’s disease.
  • HY-161643
    S21-1011
    		Inhibitor
    S21-1011 is a selective inhibitor for butyrylcholinesterase (BChE), with IC50 of 0.059 and 0.162 μM, for eqBChE and hBChE, respectively. S21-1011 exhibits good blood-brain barrier (BBB) permeability and good pharmacokinetic characters. S21-1011 exhibits anti-inflammatory activity through activation of keap1-Nrf2-ARE pathway (EC50 is 23.48 μM for antioxidant element ARE activation), ameliorates cognitive impairment in murine Alzheimer’s disease model.
  • HY-181503
    AChE/BuChE-IN-8
    		Inhibitor
    AChE/BuChE-IN-8 is a dual AChE and BuChE inhibitor, with an AChE IC50 of 1.18 μM, a human AChE Ki of 1.2 μM, and a BuChE IC50 of 2.34 μM. AChE/BuChE-IN-8 acts as an antiproliferative agent and antioxidant, exerts antiproliferative effects on colon cancer cells, scavenges free radicals, and exhibits reducing power. AChE/BuChE-IN-8 can be used in the research of Alzheimer's disease and colorectal adenocarcinoma.
  • HY-179122
    BChE-IN-45
    		Inhibitor
    BChE-IN-45 (compound 4p) is a competitive (cholinesterase) dual acting inhibitor (Ki = 11.13 μM). BChE-IN-45 has an IC50 of 13.8 μM for BChE and 35.63 μM for AChE. BChE-IN-45 can be used for research on Alzheimer's disease.
  • HY-N10701
    AChE/BChE-IN-11
    		Inhibitor
    AChE/BChE-IN-11 (compound 1) is a potent is a dual AChE and BChE inhibitor with IC50 values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research.
  • HY-161150
    AChE/BChE-IN-17
    		Inhibitor
    AChE/BChE-IN-17 (compound 8m) is a potent and non-competitiveAChE and BChE inhibitor, with IC50 values of 125.06 nM and 119.68 nM, respectively. AChE/BChE-IN-17 also inhibits α-glucosidase, with an IC50 of 41050 nM.
  • HY-W800535
    Cryptolepine
    		Inhibitor
    Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties. Cryptolepine acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, MAPK and an activator of AMPKα1/2. It intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics and induces apoptosis. Cryptolepine also exhibits anti-plasmodial and cholinesterase inhibitory activities. Cryptolepine can be used in research related to tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases and diabetes, particularly in studies focused on inhibiting tumor growth and anti-plasmodial infection.
  • HY-159898
    AChE/BChE-IN-23
    		Inhibitor
    AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model.
  • HY-170389
    BChE-IN-39
    		Inhibitor
    BChE-IN-39 (Compound 7c) is a selective inhibitor for butyrylcholinesterase (BChE) with an IC50 of 0.08 μM (IC50=3.98 μM for AChE). BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein.
  • HY-163441
    BChE-IN-31
    		Inhibitor
    BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC50 of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide.
  • HY-159081
    AChE/BChE-IN-20
    		Inhibitor
    AChE/BChE-IN-20 (compound 3m) is an acetylcholinesterase (AChE, IC50=34.81 μM) and butylcholinesterase (BChE, IC50=20.66 μM) inhibitor, which has been demonstrated to have affinity for key enzyme pockets and favorable interaction profiles by molecular docking and kinetic simulations, and can be used in the study of Alzheimer's disease.